TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34101934
Drug: NEPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA plus single-dose DEX (12 mg on day 1) with oral DEX (4 mg daily) on days 2-3 (DEX3)
Study: 34101934
Drug: DEX (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (4 mg twice daily) on days 2-4 (DEX4)
Study: 34990999
Drug: rTMS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rTMS intervention (20 daily sessions, 900 pulses per day for 4 weeks)
Study: 34091568
Drug: Nurse-led cognitive
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led cognitive behavioral therapy intervention
Study: 38042167
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (LDCT) screening
Study: 33982473
Drug: Certain herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certain herbal preparation for the treatment of non-severe influenza
Study: 33982473
Drug: Internationally recognized
Normalized name: Melanoma antigen recognized by T-cells 1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internationally recognized positive drugs or guidelines
Study: 33420076
Drug: Biological network
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological network
Study: 36432409
Drug: Fiber supplement
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber supplement
Study: 38988455
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin therapy
Study: 32811575
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin therapy with SSRIs
Study: 34755287
Drug: Quxie Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quxie Capsule combined with conventional therapy (chemotherapy, radiotherapy, targeted therapy, supportive care)
Study: 34755287
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with conventional therapy (chemotherapy, radiotherapy, targeted therapy, supportive care)
Study: 34755287
Drug: Quxie Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quxie Capsule in subgroup analysis (⩾second-line therapy, non-targeted therapy, RAS gene wild type, left-sided colon)
Study: 33367924
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy at 0.12 mJ/mm2, 2,000 impulses
Study: 33367924
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy at 0.12 mJ/mm2, 4,000 impulses
Study: 33367924
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy at 0.24 mJ/mm2, 2,000 impulses
Study: 33367924
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy at 0.24 mJ/mm2, 4,000 impulses
Study: 35181928
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment for overactive bladder
Study: 34114250
Drug: Active MDMA
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active MDMA (75-125 mg)
Study: 34114250
Drug: Placebo/control MDMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/control MDMA (0-40 mg)
Study: 32195928
Drug: Pharmacological agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological agents (not specified)
Study: 34380382
Drug: 1100 mg
Normalized name: mineral oil 1100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1100 mg coffee berry extract
Study: 34380382
Drug: 1100 mg
Normalized name: mineral oil 1100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1100 mg coffee berry extract plus 275 mg apple extract
Study: 34380382
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg coffee berry extract plus 275 mg apple extract
Study: 35649228
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion pump (HAIP) chemotherapy
Study: 35649228
Drug: Drug‐eluting beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug‐eluting beads coated with irinotecan transarterial chemoembolization
Study: 38842955
Drug: Sacral neuromodulation
Normalized name: Boswellia sacra whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral neuromodulation (SNM) therapy
Study: 33035097
Drug: SNM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNM therapy options
Study: 34544939
Drug: Intravenous Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Itraconazole 200 mg
Study: 34544939
Drug: Liposomal Amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Amphotericin B 3.0 mg/kg once daily
Study: 32053522
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous tranexamic acid (TXA) - 3 doses of 1,000 mg
Study: 32053522
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 3 doses of intravenous normal saline solution
Study: 32053522
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous tranexamic acid (TXA)
Study: 32053522
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - intravenous normal saline solution
Study: 35945094
Drug: a‐tDCS 1‐s
Approvals — FDA: no, EMA: no, PMDA: no
Description: a‐tDCS 1‐s Group (one daily a‐tDCS session)
Study: 35945094
Drug: a‐tDCS 2‐s
Approvals — FDA: no, EMA: no, PMDA: no
Description: a‐tDCS 2‐s Group (two daily a‐tDCS sessions)
Study: 35945094
Drug: Group SHAM
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group SHAM (one daily session with simulated current)
Study: 35867804
Drug: istaroxime 1.0–1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: istaroxime 1.0–1.5 μg/kg/min
Study: 32827729
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg subcutaneously once at baseline
Study: 35762581
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with cilostazol plus aspirin or clopidogrel
Study: 32481297
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment in addition to basic treatment for sepsis
Study: 32481297
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment for sepsis (Control group)
Study: 35985506
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metformin and Testosterone
Study: 36128795
Drug: Crono S-PID-50
Normalized name: PID
DrugBank: Phenindione (DB00498)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crono S-PID-50 infusion pump (CP)
Study: 33546534
Drug: Intra-dermal Platelet
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-dermal Platelet Rich Plasma (PRP) 1 ml monthly for 3 months
Study: 33546534
Drug: 50% Trichloracetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% Trichloracetic Acid (TCA) applied by CROSS technique monthly for 3 months
Study: 34550034
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg orally once daily
Study: 34550034
Drug: Enoxaparin 4000
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 4000 AxaIU (0.4 mL) subcutaneously once daily
Study: 33038432
Drug: Emricasan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan (both doses)
Study: 35241779
Drug: Mirtazapine (7.5–45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (7.5–45 mg/day)
Study: 35831082
Drug: CLEAN Meds
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLEAN Meds intervention (short list of essential medicines)
Study: 33300880
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment on the intervention side (axilla or groin)
Study: 33300880
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment on the intervention side
Study: 35337672
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with counseling sessions post-treatment
Study: 32878899
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of tranexamic acid
Study: 32878899
Drug: Severe TBI
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe TBI treatment with tranexamic acid
Study: 35576873
Drug: Magnesium +
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium + Vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily)
Study: 35576873
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D only (VitD; 1000 IU vitamin D 3 × daily)
Study: 35172779
Drug: ADT combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT combined with modified docetaxel chemotherapy (docetaxel 40 mg/m2 on the 1st day and 35 mg/m2 on the 8th day, repeated every 21 days)
Study: 35172779
Drug: ADT combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT combined with modified docetaxel chemotherapy
Study: 35172779
Drug: ADT combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT combined with standard docetaxel chemotherapy
Study: 34173659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GM EIA and BDG assay
Study: 35486948
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (MP) in combination with transdermal estradiol (t‐E2)
Study: 35486948
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) in combination with transdermal estradiol (t‐E2)
Study: 35040887
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor (ticagrelor or clopidogrel) plus therapeutic dose of heparin (n=293)
Study: 35040887
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of heparin only (usual care) (n=269)
Study: 34344399
Drug: Sapropterin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin at 10 mg/kg/day (increased up to 20 mg/kg/day) plus Phe-restricted diet in the 'sapropterin extension' group (n = 26)
Study: 32157182
Drug: Corneal stromal
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal stromal pocket irrigation with balanced salt solution
Study: 39706666
Drug: TdaP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TdaP vaccine
Study: 39706666
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine
Study: 35572853
Drug: LT4 monotherapy
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 monotherapy
Study: 33545954
Drug: Acoustic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic therapy combined with acupuncture
Study: 36036106
Drug: Intranasal acupuncture
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal acupuncture
Study: 36617611
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (budesonide nasal spray and loratadine)
Study: 32919848
Drug: Topical Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Vancomycin Powder and Dilute Povidone-Iodine Lavage (VIP)
Study: 35732183
Drug: Intervention providing
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention providing appointment and referral opportunity to community therapy
Study: 35732183
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (Intervention + TAU)
Study: 34506827
Drug: Genotype-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided treatment with ticagrelor for carriers of CYP2C19 loss-of-function alleles and clopidogrel for noncarriers.
Study: 34506827
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with clopidogrel.
Study: 33449510
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion (HS)
Study: 34081560
Drug: Methylphenidate extended-release
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODT) 20 mg daily, adjusted weekly by 10-20 mg during a 4-week dose-optimization period.
Study: 34795121
Drug: epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidermal growth factor receptor‐tyrosine kinase inhibitors
Study: 34795121
Drug: cytotoxic chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: cytotoxic chemotherapeutic agents
Study: 34795121
Drug: immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immune checkpoint inhibitors
Study: 34075841
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Ellagic Acid (100 mg) plus Annona Muricata (100 mg), daily for 6 months
Study: 32475446
Drug: Star anise
Normalized name: STAR ANISE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Star anise oil (SAO) supplementation at 400 mg/kg
Study: 32475446
Drug: Star anise
Normalized name: STAR ANISE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Star anise oil (SAO) supplementation at 200 mg/kg
Study: 32475446
Drug: Star anise
Normalized name: STAR ANISE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Star anise oil (SAO) supplementation at 600 mg/kg
Study: 32475446
Drug: Star anise
Normalized name: STAR ANISE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Star anise oil (SAO) supplementation at 0 mg/kg (control)
Study: 36862239
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg dexamethasone daily
Study: 36862239
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg dexamethasone daily
Study: 33148620
Drug: FOLFOXIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI plus bevacizumab (irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 3200 mg/m2)
Study: 33148620
Drug: FOLFOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX plus bevacizumab (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 then 2400 mg/m2)
Study: 33308359
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid daily)
Study: 33308359
Drug: Enalapril only
Normalized name: Enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril only (10 mg daily)
Study: 36244527
Drug: Gabapentin (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1800 mg/day)
Study: 33251687
Drug: Deep injection
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep injection technique targeting the supraperiosteal plane
Study: 33251687
Drug: Superficial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial injection technique in the superficial fatty layer
Study: 33371123
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with conventional treatment (treatment A) for 6 weeks
Study: 33371123
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (treatment C) for 6 weeks
Study: 33371123
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with conventional treatment (treatment A)
Study: 33371123
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (treatment C)
Study: 34676916
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants (IL)
Study: 34676916
Drug: 3-month post-placement
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month post-placement loaded implants (DL)
Study: 34676916
Drug: Platform switched
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform switched implants
Study: 34676916
Drug: Platform matching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform matching implants
Study: 33257485
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for 6 months
Study: 38958846
Drug: Olaparib monotherapy
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib monotherapy
Study: 33369580
Drug: Olaparib in
Normalized name: Product containing olaparib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib in combination with bevacizumab
Study: 35437789
Drug: Culturally Informed
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Informed and Flexible Family Treatment for Adolescents (CIFFTA)
Study: 35437789
Drug: Individually Oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually Oriented Treatment‐As‐Usual (ITAU)
Study: 33022293
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (n=12, 11%)
Study: 33022293
Drug: Numerous antivirals
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Numerous antivirals and immune enhancers
Study: 33796955
Drug: Caffeine gel
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine gel with 1% choline geranate
Study: 33796955
Drug: Caffeine gel
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine gel without ionic liquid
Study: 32536547
Drug: RTS,S/AS02 malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02 malaria vaccine
Study: 35067080
Drug: LIA +
Normalized name: Lithium Iodide Ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA + continuous postoperative infusion of local anaesthetic for 48 hours
Study: 35472097
Drug: Energy-dense enteral
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-dense enteral nutrition (1.5 kcal/mL)
Study: 35472097
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral nutrition (1.0 kcal/mL)
Study: 35472097
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with GRV ≥250 mL
Study: 32917418
Drug: Increased intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased intramuscular adipose tissue of the quadriceps
Study: 32917418
Drug: Subcutaneous fat
Normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fat thickness of the thigh
Study: 36544075
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of RBX2660 + one dose of placebo
Study: 36544075
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of RBX2660
Study: 37315558
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of placebo
Study: 36544075
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of RBX2660 + one dose of placebo (per-protocol population)
Study: 36544075
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of placebo (per-protocol population)
Study: 36544075
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of RBX2660 (per-protocol population)
Study: 32871704
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) treatment for 8 weeks (n = 18)
Study: 32871704
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) for 4 weeks followed by OLP for 4 weeks (n = 20)
Study: 34132703
Drug: Postoperative monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative monotherapy with PT
Study: 34132703
Drug: Standard 2-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 2-drug therapy with CM